drugset
drugset / Trial / NCT04975958

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

NCT04975958 ↗

Phase 1 Completed 47 enrolled Adlai Nortye Biopharma Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, Phase 1a study to evaluate the safety, tolerability, PK and preliminary efficacy of AN2025 and AN0025 in double or triple combination treatments with Atezolizumab in patients with locally advanced/metastatic tumors.

Timeline

Start
2021-09-07
Primary completion
2025-01-24
Completion
2025-01-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody 1200 mg Intravenous
Subject Buparlisib Small molecule 50 mg Oral
Subject Buparlisib Small molecule 80 mg Oral
Subject Buparlisib Small molecule 100 mg Oral
Subject PALUPIPRANT Small molecule 125 mg Oral
Subject PALUPIPRANT Small molecule 250 mg Oral
Subject PALUPIPRANT Small molecule 500 mg Oral

Indications

No indication recorded.